Linked e-resources
Details
Table of Contents
Intro; Preface; Acknowledgements; Overview; Contents; About the Authors; Abbreviations; 1: Introduction; 1.1 Introduction to Analytical Methods; 1.2 History of Chromatography; 1.3 High-Performance Liquid Chromatography; 1.3.1 High-Performance Adsorption Chromatography; 1.3.2 High-Performance Partition Chromatography; 1.3.3 High-Performance Ion-Exchange Chromatography; 1.3.4 High-Performance Size-Exclusion Chromatography; 1.4 Instrumentation of High-Performance Liquid Chromatography [9-13]; 1.4.1 Mobile Phase Reservoir; 1.4.2 Pumping System; 1.4.3 Sample Injection System
1.4.4 Stationary Phase (Column)1.4.5 Detector; 1.4.6 Data System; 1.4.7 Backpressure Regulator; 1.5 Applications of HPLC; 1.6 General Considerations for HPLC Method Development; 1.6.1 Various Steps for Method Development [15, 16]; 1.6.2 Optimization of the Method Development Parameters [17, 18]; 1.7 HPLC Method Validation [19-23]; 1.7.1 Validation Parameters; 1.7.1.1 Different Validation Parameters; 1.7.1.2 Statistical Validation [24, 25]; 1.8 System Suitability [26, 27]; 1.8.1 Capacity Factor; 1.8.2 Efficiency; 1.8.3 Selectivity; 1.8.4 Resolution; 1.8.5 Tailing Factor
1.8.6 Asymmetry Factor1.9 Stability-Indicating Method Development [28-30]; 1.9.1 Objective of Stability Studies; 1.9.2 Stability Protocols [31]; 1.9.3 Degradation Pathways and Their Role in SIM Development; 1.9.3.1 Need of Stress Testing in SIMs; References; 2: Research Envisaged; 2.1 Plan of Work; 3: Drug(s) Profile; 3.1 Ambroxol Hydrochloride; 3.1.1 Description [1-3]; 3.1.2 Pharmacopoeial Specifications; 3.1.3 Pharmacology [7-10]; 3.1.4 Adverse Effect; 3.1.5 Drug Interaction; 3.1.6 Doses; 3.1.7 Brand Name; 3.2 Cetirizine Hydrochloride; 3.2.1 Description [1-3]
3.2.2 Pharmacopoeial Specifications3.2.3 Pharmacology; 3.2.4 Interaction Studies; 3.2.5 Toxicity; 3.2.6 Side Effects; 3.2.7 Adverse Effects; 3.2.8 Dosage and Safety [17, 18]; 3.2.9 Brand Names; 3.3 Chlorpheniramine Maleate; 3.3.1 Description [2, 3]; 3.3.2 Pharmacopoeial Specifications [4-6]; 3.3.3 Pharmacological Action; 3.3.4 Indications and Usage; 3.3.5 Adverse Effects; 3.3.6 Drug Interactions; 3.3.7 Doses [14, 15]; 3.3.8 Dosage Forms [16]; 3.3.9 Brand Names; 3.4 Guaiphenesin; 3.4.1 Descriptions [1-3]; 3.4.2 Pharmacopoeial Specifications [4-6]; 3.4.3 Pharmacology
3.4.4 Adverse Effect3.4.5 Drug Interaction; 3.4.6 Dose; 3.4.7 Brand Names; 3.5 Paracetamol; 3.5.1 Description; 3.5.2 Pharmacopoeial Specifications [4-6]; 3.5.3 Pharmacological Action; 3.5.4 Indications and Usage; 3.5.5 Adverse Effects; 3.5.6 Drug Interactions; 3.5.7 Doses; 3.5.8 Dosage Forms; 3.5.9 Brand Names; 3.6 Phenylephrine Hydrochloride; 3.6.1 Description [1-3]; 3.6.2 Pharmacopoeial Specifications [4-6]; 3.6.3 Pharmacological Action; 3.6.4 Indications and Usage; 3.6.5 Adverse Effects; 3.6.6 Contraindications; 3.6.7 Overdose; 3.6.8 Drug Interactions; 3.6.9 Doses [17].
1.4.4 Stationary Phase (Column)1.4.5 Detector; 1.4.6 Data System; 1.4.7 Backpressure Regulator; 1.5 Applications of HPLC; 1.6 General Considerations for HPLC Method Development; 1.6.1 Various Steps for Method Development [15, 16]; 1.6.2 Optimization of the Method Development Parameters [17, 18]; 1.7 HPLC Method Validation [19-23]; 1.7.1 Validation Parameters; 1.7.1.1 Different Validation Parameters; 1.7.1.2 Statistical Validation [24, 25]; 1.8 System Suitability [26, 27]; 1.8.1 Capacity Factor; 1.8.2 Efficiency; 1.8.3 Selectivity; 1.8.4 Resolution; 1.8.5 Tailing Factor
1.8.6 Asymmetry Factor1.9 Stability-Indicating Method Development [28-30]; 1.9.1 Objective of Stability Studies; 1.9.2 Stability Protocols [31]; 1.9.3 Degradation Pathways and Their Role in SIM Development; 1.9.3.1 Need of Stress Testing in SIMs; References; 2: Research Envisaged; 2.1 Plan of Work; 3: Drug(s) Profile; 3.1 Ambroxol Hydrochloride; 3.1.1 Description [1-3]; 3.1.2 Pharmacopoeial Specifications; 3.1.3 Pharmacology [7-10]; 3.1.4 Adverse Effect; 3.1.5 Drug Interaction; 3.1.6 Doses; 3.1.7 Brand Name; 3.2 Cetirizine Hydrochloride; 3.2.1 Description [1-3]
3.2.2 Pharmacopoeial Specifications3.2.3 Pharmacology; 3.2.4 Interaction Studies; 3.2.5 Toxicity; 3.2.6 Side Effects; 3.2.7 Adverse Effects; 3.2.8 Dosage and Safety [17, 18]; 3.2.9 Brand Names; 3.3 Chlorpheniramine Maleate; 3.3.1 Description [2, 3]; 3.3.2 Pharmacopoeial Specifications [4-6]; 3.3.3 Pharmacological Action; 3.3.4 Indications and Usage; 3.3.5 Adverse Effects; 3.3.6 Drug Interactions; 3.3.7 Doses [14, 15]; 3.3.8 Dosage Forms [16]; 3.3.9 Brand Names; 3.4 Guaiphenesin; 3.4.1 Descriptions [1-3]; 3.4.2 Pharmacopoeial Specifications [4-6]; 3.4.3 Pharmacology
3.4.4 Adverse Effect3.4.5 Drug Interaction; 3.4.6 Dose; 3.4.7 Brand Names; 3.5 Paracetamol; 3.5.1 Description; 3.5.2 Pharmacopoeial Specifications [4-6]; 3.5.3 Pharmacological Action; 3.5.4 Indications and Usage; 3.5.5 Adverse Effects; 3.5.6 Drug Interactions; 3.5.7 Doses; 3.5.8 Dosage Forms; 3.5.9 Brand Names; 3.6 Phenylephrine Hydrochloride; 3.6.1 Description [1-3]; 3.6.2 Pharmacopoeial Specifications [4-6]; 3.6.3 Pharmacological Action; 3.6.4 Indications and Usage; 3.6.5 Adverse Effects; 3.6.6 Contraindications; 3.6.7 Overdose; 3.6.8 Drug Interactions; 3.6.9 Doses [17].